I don't see how we could:
Miss getting the continuation decision by the Data and Safety Monitoring Board in the Acute Graft versus Host Disease trial;
Miss being the drug used in the Novavax prototype covid vaccine, which caused European regulators to request more data, and which may have shut down the NVAX shareholders' lawsuit claiming that there was no effective prototype vaccine. The prototype vaccine had to go through a clinical trial, unlike the updated vaccine, which was approved based on non-clinical trial data;
Miss getting EUL or EUA authorization for covid which, if obtained, will open up our market to the prophylaxis use of lenz as a vaccine adjuvant, in addition to the therapeutic use to treat infected patients;
Miss getting an expedited approval to treat CMML from the Australian government, complete with a possible $100M+ Priority Review Voucher;
Miss executing the recall of our loaned shares, which I think will be the biggest ever seen, and will make millionaires of some of us who already have every share of Humanigen stock we have been able to buy;
Miss a business restructuring that will lead the way back to the Nasdaq, with partners who will be handling our distribution and commercialization as they use lenz to strengthen the safety and efficacy of their own products and platforms, such as CAR-T;
Miss saving the lives of millions of people worldwide, who will only suffer preventable deaths under existing standard of care, especially if a new covid variant begins circulating that it far stronger and transmissible than any previous variant;
Miss preventing trillions of dollars in damage to the worldwide economies and societies.
Thank you for asking. And thank management for their steadfast effort to make this happen.
